Table 2.

Transplant characteristics in the observational study of allogeneic transplant patients receiving myeloablative conditioning regimen of cyclophosphamide and total body radiation (TBI) at different doses between 2001 and 2013.

Characteristics	12 Gy (n=1745) n (%)	13–13.75 Gy (n=648) n (%)	14 Gy (n=328) n (%)	P-value
Time from diagnosis to transplant, median (range), months	7 (1–252)	7 (2–310)	6 (1–222)	0.44
Number of fractions, median (range)	6 (2–12)	8 (3–12)	7 (2–8)	<0.001
TBI dose per fraction, median (range), cGy	200 (100–600)	165 (108–440)	200 (175–700)	<0.001
Cy dose, median (range), mg/kg	120 (34–240)	120 (36–239)	90 (33–206)	<0.001
Donor type				<0.001
HLA-identical sibling	746 (43)	216 (33)	109 (33)
Matched unrelated (8/8)	694 (40)	313 (48)	164 (50)
Partially matched unrelated (7/8)	305 (17)	119 (18)	55 (17)
Graft source				<0.001
Bone marrow	504 (29)	228 (35)	79 (24)
Peripheral blood	1241 (71)	420 (65)	249 (76)
Donor–Recipient sex match				0.37
Male–Male	606 (35)	218 (34)	114 (35)
Male–Female	446 (26)	176 (27)	78 (24)
Female–Male	347 (20)	125 (19)	55 (17)
Female–Female	338 (19)	128 (20)	81 (25)
Not reported	8 (<1)	1 (<1)	0
Donor–Recipient cytomegalovirus status				0.02
−/−	510 (29)	157 (24)	99 (30)
−/+	429 (25)	183 (28)	96 (29)
+/−	193 (11)	63 (10)	38 (12)
+/+	527 (30)	207 (32)	76 (23)
Not reported	86 (5)	38 (6)	19 (6)
Unrelated donor age, median (range), years	33 (19–61)	33 (18–58)	32 (19–60)	0.95
Year of transplant				0.005
2001–2005	809 (46)	267 (41)	149 (45)
2006–2010	749 (43)	308 (48)	161 (49)
2011–2013	187 (11)	73 (11)	18 (5)
Inpatient days, median (range)	29 (<1–123)	32 (<1–175)	26 (<1–100)
Median follow-up of survivors, range, months	72 (3 – 167)	67 (4 – 148)	72 (5 – 144)

Abbreviations: Cy, cyclophosphamide; HLA, human leukocyte antigen; TBI, total-body irradiation